Literature DB >> 16237041

The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis.

Floris van Gaalen1, Andreea Ioan-Facsinay, Tom W J Huizinga, René E M Toes.   

Abstract

Rheumatoid arthritis is a chronic inflammatory autoimmune disease of unknown cause. The immune response against citrullinated Ags has recently become the prime suspect for disease pathogenesis. Immunity against citrullinated Ags is thought to play a pivotal role in the disease for several reasons: 1) citrullinated Ags are expressed in the target organ, the inflamed joint; 2) anti-citrullinated protein Abs are present before the disease becomes manifest; and 3) these Abs are highly specific for rheumatoid arthritis. In this review, data from clinical, genetic, biochemical, and animal studies is combined to create a profile of this remarkable autoantibody response. Moreover, a model is proposed of how the anti-citrullinated proteins response is generated and how it could eventually lead to chronic inflammation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16237041     DOI: 10.4049/jimmunol.175.9.5575

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

Review 1.  Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.

Authors:  Emilio Martin-Mola; Alejandro Balsa; Rosario García-Vicuna; Juan Gómez-Reino; Miguel Angel González-Gay; Raimon Sanmartí; Estíbaliz Loza
Journal:  Rheumatol Int       Date:  2016-06-06       Impact factor: 2.631

Review 2.  Cellular and molecular perspectives in rheumatoid arthritis.

Authors:  Douglas J Veale; Carl Orr; Ursula Fearon
Journal:  Semin Immunopathol       Date:  2017-05-15       Impact factor: 9.623

3.  The major risk alleles of age-related macular degeneration (AMD) in CFH do not play a major role in rheumatoid arthritis (RA).

Authors:  L A Trouw; S Böhringer; N A Daha; E A Stahl; S Raychaudhuri; F A Kurreeman; G Stoeken-Rijsbergen; J J Houwing-Duistermaat; T W Huizinga; R E Toes
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

4.  The relationship between the presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis.

Authors:  Mohammed Z Cader; Andrew D Filer; Christopher D Buckley; Karim Raza
Journal:  BMC Musculoskelet Disord       Date:  2010-08-23       Impact factor: 2.362

5.  Antibodies to mutated citrullinated vimentin in rheumatoid arthritis: diagnostic value, association with radiological damage and axial skeleton affection.

Authors:  Howaida E Mansour; Khaled M Metwaly; Iman A Hassan; Hebat-Allah A Elshamy; Moataz M S Elbeblawy
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2010-05-24

6.  Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis.

Authors:  Hannah Poulsom; Peter J Charles
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

Review 7.  The role of anti-cyclic cytrullinate antibodies testing in rheumatoid arthritis.

Authors:  Cristiano Alessandri; Roberta Priori; Mariagrazia Modesti; Riccardo Mancini; Guido Valesini
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

8.  Share epitope, citrullinated cyclic peptide antibodies and smoking in Brazilian rheumatoid arthritis patients.

Authors:  Rene Donizeti Oliveira; Cristina Maria Junta; Fabíola Reis Oliveira; Lucienir Maria Silva; Eduardo Antonio Donadi; Paulo Louzada-Junior
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

9.  Effect of tobacco smoking on tissue protein citrullination and disease progression in patients with rheumatoid arthritis.

Authors:  Mahmoud M Alsalahy; Hamdy S Nasser; Manal M Hashem; Sahar M Elsayed
Journal:  Saudi Pharm J       Date:  2010-02-20       Impact factor: 4.330

10.  Autoimmune responses in the rheumatoid synovium.

Authors:  Rene E M Toes; Tom W J Huizinga
Journal:  PLoS Med       Date:  2009-01-13       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.